Maraviroc NDC 70710-1930

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1930Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1930Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1930-6	70710193006	60 TABLET, FILM COATED in 1 BOTTLE (70710-1930-6)Marketed from May 23, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Maraviroc
Generic name (nonproprietary): maraviroc
Active ingredients: Maraviroc — 150 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217880
Marketing start: May 23, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Chemokine Co-receptor 5 Antagonists (Mechanism)
Identifiers: Product ID 70710-1930_b9cfbc86-86a5-487f-8b6d-1e9607d2f8f7SPL ID b9cfbc86-86a5-487f-8b6d-1e9607d2f8f7SPL set ID 9bba17ba-0bc5-430c-96d1-c568e236a0edRxCUI 728223, 728225UNII MD6P741W8AUPC 0370710193065, 0370710193164
Pharmacologic class: CCR5 Co-receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710193006 followed by a unit qualifier and the quantity

Package 70710-1930-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 15, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. Limitations of Use: Maraviroc tablets are not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology ( 12.4 )]. Maraviroc tablet is a CCR5 co-receptor antagonist indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. ( 1 ) Limitations of Use: Not recommended in patients with dual…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217880

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217880
Product	Strength	Form · route	Labeler	Product NDC
Maraviroc	Maraviroc 300 mg/1	Tablet, Film coatedOral	Navinta LLC	68475-007
Maraviroc	Maraviroc 150 mg/1	Tablet, Film coatedOral	Navinta LLC	68475-008
Maraviroc	Maraviroc 300 mg/1	Tablet, Film coatedOral	Zydus Pharmaceuticals USA Inc.	70710-1931